Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus

•COMBI-APlus met its primary endpoint of reduction in the composite rate of pyrexia.•Pyrexia composite rate = grade 3/4 incidence, hospitalisation, and discontinuation.•The adapted pyrexia management algorithm interrupted both drugs for pyrexia.•Overall safety and early efficacy in COMBI-APlus were consistent with COMBI-AD.